Skip to Main Content

Editor's Choice Articles

Explore the high-quality articles published in NAR Cancer that have been hand-picked by Editor-in-Chief William Dynan. The journal is fully open access, meaning all articles are freely available to read and download. 
A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment
Rona Merdler-Rabinowicz and others
NAR Cancer, Volume 7, Issue 2, June 2025, zcaf016, https://doi.org/10.1093/narcan/zcaf016
Adenosine deaminases acting on RNA (ADAR) enzymes constitute a natural cellular mechanism that induces A-to-I(G) editing, introducing genetic changes at the RNA level. Recently, interest in the endogenous-ADAR editor has emerged for correcting genetic mutations, consisting of a programmed ...
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress
Jay R Anand and others
NAR Cancer, Volume 7, Issue 1, March 2025, zcaf009, https://doi.org/10.1093/narcan/zcaf009
Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA damage response (DDR) mechanisms for cell survival. Different oncogenic stimuli signal via distinct mechanisms in every cancer setting. The DDR is also pathologically reprogrammed and ...
Decoding the molecular symphony: interactions between the m6A and p53 signaling pathways in cancer
Rachel Shoemaker and others
NAR Cancer, Volume 6, Issue 3, September 2024, zcae037, https://doi.org/10.1093/narcan/zcae037
The p53 tumor suppressor gene governs a multitude of complex cellular processes that are essential for anti-cancer function and whose dysregulation leads to aberrant gene transcription, activation of oncogenic signaling and cancer development. Although mutations can occur at any point in the ...
Intrinsic PARG inhibitor sensitivity is mimicked by TIMELESS haploinsufficiency and rescued by nucleoside supplementation
Camilla Coulson-Gilmer and others
NAR Cancer, Volume 6, Issue 3, September 2024, zcae030, https://doi.org/10.1093/narcan/zcae030
A subset of cancer cells are intrinsically sensitive to inhibitors targeting PARG, the poly(ADP-ribose) glycohydrolase that degrades PAR chains. Sensitivity is accompanied by persistent DNA replication stress, and can be induced by inhibition of TIMELESS , a replisome accelerator. However, the ...
HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression
Hongbo Ling and others
NAR Cancer, Volume 6, Issue 2, June 2024, zcae018, https://doi.org/10.1093/narcan/zcae018
Secreted protein acidic and rich in cysteine (SPARC), a conserved secreted glycoprotein, plays crucial roles in regulating various biological processes. SPARC is highly expressed and has profound implications in several cancer types, including melanoma. Understanding the mechanisms that govern ...
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
Jonatan L Gabre and others
NAR Cancer, Volume 6, Issue 1, March 2024, zcad062, https://doi.org/10.1093/narcan/zcad062
Neuroblastoma (NB) is the most common cancer in infancy with an urgent need for more efficient targeted therapies. The development of novel (combinatorial) treatment strategies relies on extensive explorations of signaling perturbations in neuroblastoma cell lines, using RNA-Seq or other high ...
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination
Victoria E Brown and others
NAR Cancer, Volume 5, Issue 3, September 2023, zcad039, https://doi.org/10.1093/narcan/zcad039
CCNE1 amplification is a common alteration in high-grade serous ovarian cancer and occurs in 15–20% of these tumors. These amplifications are mutually exclusive with homologous recombination deficiency, and, as they have intact homologous recombination, are intrinsically resistant to poly ...
Effectively utilizing publicly available databases for cancer target evaluation
Daniel Croft and others
NAR Cancer, Volume 5, Issue 3, September 2023, zcad035, https://doi.org/10.1093/narcan/zcad035
The majority of compounds designed against cancer drug targets do not progress to become approved drugs, mainly due to lack of efficacy and/or unmanageable toxicity. Robust target evaluation is therefore required before progressing through the drug discovery process to reduce the high attrition ...
DNA mismatch repair in cancer immunotherapy
Junhong Guan and Guo-Min Li
NAR Cancer, Volume 5, Issue 3, September 2023, zcad031, https://doi.org/10.1093/narcan/zcad031
Tumors defective in DNA mismatch repair (dMMR) exhibit microsatellite instability (MSI). Currently, patients with dMMR tumors are benefitted from anti-PD-1/PDL1-based immune checkpoint inhibitor (ICI) therapy. Over the past several years, great progress has been made in understanding the mechanisms ...
Molecular origins of mutational spectra produced by the environmental carcinogen N-nitrosodimethylamine and SN1 chemotherapeutic agents
Amanda L Armijo and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad015, https://doi.org/10.1093/narcan/zcad015
DNA-methylating environmental carcinogens such as N -nitrosodimethylamine (NDMA) and certain alkylators used in chemotherapy form O 6 -methylguanine (m6G) as a functionally critical intermediate. NDMA is a multi-organ carcinogen found in contaminated water, polluted air, preserved foods, tobacco ...
Oncogenic ERRB2 signals through the AP-1 transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma
Samuel Ogden and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcad001, https://doi.org/10.1093/narcan/zcad001
Oesophageal adenocarcinoma (OAC) is a deadly disease with poor survival statistics and few targeted therapies available. One of the most common molecular aberrations in OAC is amplification or activation of the gene encoding the receptor tyrosine kinase ERBB2, and ERBB2 is targeted in the clinic ...
Pancan-MNVQTLdb: systematic identification of multi-nucleotide variant quantitative trait loci in 33 cancer types
Dongyang Wang and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac043, https://doi.org/10.1093/narcan/zcac043
Multi-nucleotide variants (MNVs) are defined as clusters of two or more nearby variants existing on the same haplotype in an individual. Recent studies have identified millions of MNVs in human populations, but their functions remain largely unknown. Numerous studies have demonstrated that ...
Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors
Jiakai Hou and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac038, https://doi.org/10.1093/narcan/zcac038
Genetic screens are widely exploited to develop novel therapeutic approaches for cancer treatment. With recent advances in single-cell technology, single-cell CRISPR screen (scCRISPR) platforms provide opportunities for target validation and mechanistic studies in a high-throughput manner. Here, we ...
Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
Vanessa Vermeirssen and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac037, https://doi.org/10.1093/narcan/zcac037
While cell-free DNA (cfDNA) is widely being investigated, free circulating RNA (extracellular RNA, exRNA) has the potential to improve cancer therapy response monitoring and detection due to its dynamic nature. However, it remains unclear in which blood subcompartment tumour-derived exRNAs ...
KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers
Xiaoju Hu and others
NAR Cancer, Volume 4, Issue 3, September 2022, zcac023, https://doi.org/10.1093/narcan/zcac023
The histone methyltransferase KMT2C is among the most frequently mutated epigenetic modifier genes in cancer and plays an essential role in MRE11-dependent DNA replication fork restart. However, the effects of KMT2C deficiency on genomic instability during tumorigenesis are unclear. Analyzing 9,663 ...
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Kevin J Thompson and others
NAR Cancer, Volume 4, Issue 2, June 2022, zcac018, https://doi.org/10.1093/narcan/zcac018
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical ...
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery
Soner Koc and others
NAR Cancer, Volume 4, Issue 2, June 2022, zcac014, https://doi.org/10.1093/narcan/zcac014
We created the PDX Network (PDXNet) portal ( https://portal.pdxnetwork.org/ ) to centralize access to the National Cancer Institute-funded PDXNet consortium resources, to facilitate collaboration among researchers and to make these data easily available for research. The portal includes sections ...
Quantification of radiation-induced DNA double strand break repair foci to evaluate and predict biological responses to ionizing radiation
Sébastien Penninckx and others
NAR Cancer, Volume 3, Issue 4, December 2021, zcab046, https://doi.org/10.1093/narcan/zcab046
Radiation-induced foci (RIF) are nuclear puncta visualized by immunostaining of proteins that regulate DNA double-strand break (DSB) repair after exposure to ionizing radiation. RIF are a standard metric for measuring DSB formation and repair in clinical, environmental and space radiobiology. The ...
Oxidative stress-mediated epigenetic regulation by G-quadruplexes
Aaron M Fleming and Cynthia J Burrows
NAR Cancer, Volume 3, Issue 3, September 2021, zcab038, https://doi.org/10.1093/narcan/zcab038
Many cancer-associated genes are regulated by guanine (G)-rich sequences that are capable of refolding from the canonical duplex structure to an intrastrand G-quadruplex. These same sequences are sensitive to oxidative damage that is repaired by the base excision repair glycosylases OGG1 and ...
SCISSOR™: a single-cell inferred site-specific omics resource for tumor microenvironment association study
Xiang Cui and others
NAR Cancer, Volume 3, Issue 3, September 2021, zcab037, https://doi.org/10.1093/narcan/zcab037
Tumor tissues are heterogeneous with different cell types in tumor microenvironment, which play an important role in tumorigenesis and tumor progression. Several computational algorithms and tools have been developed to infer the cell composition from bulk transcriptome profiles. However, they ...
EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer
Hwa-Ryeon Kim and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab023, https://doi.org/10.1093/narcan/zcab023
Cancer cells utilize epigenetic alterations to acquire autonomous capabilities for tumor maintenance. Here, we show that pancreatic ductal adenocarcinoma (PDA) cells utilize super-enhancers (SEs) to activate the transcription factor EVI1 (ecotropic viral integration site 1) gene, resulting in ...
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Amrita Sule and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab018, https://doi.org/10.1093/narcan/zcab018
Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite ...
The structure of APOBEC1 and insights into its RNA and DNA substrate selectivity
Aaron D Wolfe and others
NAR Cancer, Volume 2, Issue 4, December 2020, zcaa027, https://doi.org/10.1093/narcan/zcaa027
APOBEC1 (APO1), a member of AID/APOBEC nucleic acid cytosine deaminase family, can edit apolipoprotein B mRNA to regulate cholesterol metabolism. This APO1 RNA editing activity requires a cellular cofactor to achieve tight regulation. However, no cofactors are required for deamination on DNA by ...
Pan-cancer proteogenomic analysis reveals long and circular noncoding RNAs encoding peptides
Ghofran Othoum and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa015, https://doi.org/10.1093/narcan/zcaa015
Recent studies show that annotated long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) encode for stable, functional peptides that contribute to human development and disease. To systematically discover lncRNAs and circRNAs encoding peptides, we performed a comprehensive integrative analysis ...
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close